| Drug Name |
Panitumumab |
| Drug ID |
BADD_D01666 |
| Description |
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.[L17663] |
| Indications and Usage |
For the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01FE02 |
| DrugBank ID |
DB01269
|
| KEGG ID |
D05350
|
| MeSH ID |
D000077544
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0HU9H
|
| NDC Product Code |
55513-956; 55513-954 |
| UNII |
6A901E312A
|
| Synonyms |
Panitumumab | Panitumumab Antibody, Human | Human Panitumumab Antibody | ABX-EGF MAb | ABX-EGF Monoclonal Antibody | ABX EGF Monoclonal Antibody | Monoclonal Antibody, ABX-EGF | Vectibix |
